ECSP034600A - Compuestos de lactama - Google Patents

Compuestos de lactama

Info

Publication number
ECSP034600A
ECSP034600A EC2003004600A ECSP034600A ECSP034600A EC SP034600 A ECSP034600 A EC SP034600A EC 2003004600 A EC2003004600 A EC 2003004600A EC SP034600 A ECSP034600 A EC SP034600A EC SP034600 A ECSP034600 A EC SP034600A
Authority
EC
Ecuador
Prior art keywords
lactama
compounds
alaninyl
methylbutyryl
benzazepin
Prior art date
Application number
EC2003004600A
Other languages
English (en)
Inventor
Varghese John
Eugene D Thorsett
Jeffrey Nissen
Lee H Latimer
James E Audia
Jay S Tung
Stacey Leigh Mcdaniel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ECSP034600A publication Critical patent/ECSP034600A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona el compuesto (N)- (S)-2-hidroxi-3- metilbutiril)-1- (l-alaninil) -(S)- 1-amino-3-metil-4, 5, 6, 7- tetrahidro-2H-3-benzazepin-2-ona.
EC2003004600A 2000-11-17 2003-05-13 Compuestos de lactama ECSP034600A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24955200P 2000-11-17 2000-11-17

Publications (1)

Publication Number Publication Date
ECSP034600A true ECSP034600A (es) 2003-06-25

Family

ID=22943982

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2003004600A ECSP034600A (es) 2000-11-17 2003-05-13 Compuestos de lactama

Country Status (33)

Country Link
US (1) US20050261495A1 (es)
EP (1) EP1341531B1 (es)
JP (1) JP4116437B2 (es)
KR (1) KR100819679B1 (es)
CN (1) CN1486184A (es)
AR (1) AR035927A1 (es)
AU (2) AU4319202A (es)
BR (1) BR0115427A (es)
CA (1) CA2427227C (es)
CY (1) CY1106366T1 (es)
CZ (1) CZ20031351A3 (es)
DE (1) DE60126132T2 (es)
DK (1) DK1341531T3 (es)
DZ (1) DZ3453A1 (es)
EA (1) EA005954B1 (es)
EC (1) ECSP034600A (es)
ES (1) ES2278804T3 (es)
HR (1) HRP20030383B1 (es)
HU (1) HU228117B1 (es)
IL (2) IL155960A0 (es)
MX (1) MXPA03004292A (es)
MY (1) MY134559A (es)
NO (1) NO324324B1 (es)
NZ (1) NZ525854A (es)
PE (1) PE20020802A1 (es)
PL (1) PL212199B1 (es)
PT (1) PT1341531E (es)
SI (1) SI1341531T1 (es)
SK (1) SK288065B6 (es)
TW (1) TWI305204B (es)
UA (1) UA74849C2 (es)
WO (1) WO2002047671A2 (es)
ZA (1) ZA200303789B (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
EP1867636B1 (en) 2005-04-08 2013-06-05 Daiichi Sankyo Company, Limited Pyridylmethylsulfone derivative
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
WO2007088878A1 (ja) * 2006-01-31 2007-08-09 Api Corporation ベンゾアゼピノン類の製造方法
JP2010518064A (ja) 2007-02-12 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション Ａｄおよび関連状態の治療のためのピペラジン誘導体
CL2008002060A1 (es) * 2007-07-16 2008-11-21 Wyeth Corp Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
US8188069B2 (en) 2007-08-14 2012-05-29 Eli Lilly And Company Azepine derivatives as gamma-secretase inhibitors
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
HRP20130552T1 (en) 2007-12-21 2013-08-31 Ligand Pharmaceuticals, Inc. Selective androgen receptor modulators (sarms) and uses thereof
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
CN104945382B (zh) 2009-10-14 2020-02-07 默沙东公司 提高p53活性的取代的哌啶和其用途
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP3587574B1 (en) 2010-08-17 2022-03-16 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
WO2012030685A2 (en) 2010-09-01 2012-03-08 Schering Corporation Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
EP3970725B1 (en) 2012-09-07 2025-08-20 Massachusetts Eye & Ear Infirmary A gamma secretase inhibitor for treating hearing loss
CN112359018A (zh) 2012-09-07 2021-02-12 麻省眼耳医院 用于再生毛细胞和/或支持细胞的方法及组合物
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
RS56680B1 (sr) 2012-11-28 2018-03-30 Merck Sharp & Dohme Kompozicije i postupci za lečenje kancera
MX373639B (es) 2012-12-20 2020-05-04 Merck Sharp & Dohme Imidazopiridinas sustituidas como inhibidores de doble minuto 2 humana.
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
US20160067306A1 (en) 2013-04-19 2016-03-10 National University Corporation Hokkaido University Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
EP3094323A4 (en) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
WO2016069906A1 (en) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
AU2017268078B2 (en) 2016-05-16 2023-03-02 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2019148067A1 (en) 2018-01-26 2019-08-01 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
KR20210046009A (ko) 2018-08-07 2021-04-27 머크 샤프 앤드 돔 코포레이션 Prmt5 억제제
US11993602B2 (en) 2018-08-07 2024-05-28 Merck Sharp & Dohme Llc PRMT5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
AU2020257397A1 (en) 2019-04-19 2021-12-16 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
EP4076459A4 (en) 2019-12-17 2023-12-20 Merck Sharp & Dohme LLC Prmt5 inhibitors
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
EP4077282A4 (en) 2019-12-17 2023-11-08 Merck Sharp & Dohme LLC Prmt5 inhibitors
CA3265870A1 (en) 2022-09-02 2024-03-07 Merck Sharp & Dohme Llc Pharmaceutical compositions based on topoisomerase-1 inhibitors derived from Exatecan, and their uses
KR20250079227A (ko) 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
IL321395A (en) 2022-12-14 2025-08-01 Merck Sharp & Dohme Llc Auristatin cargo-linkers, pharmaceutical compounds, and their uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL196641B1 (pl) * 1996-12-23 2008-01-31 Elan Pharm Inc Związki laktamowe i środek farmaceutyczny
EP1089977A1 (en) * 1998-06-22 2001-04-11 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
WO2001034571A1 (en) * 1999-11-09 2001-05-17 Eli Lilly And Company β-AMINOACID COMPOUNDS USEFUL FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS
JP2005538031A (ja) * 2000-11-17 2005-12-15 イーライ・リリー・アンド・カンパニー ラクタム化合物
UA77165C2 (en) * 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam

Also Published As

Publication number Publication date
ZA200303789B (en) 2004-08-16
JP4116437B2 (ja) 2008-07-09
CA2427227C (en) 2010-08-17
KR20030051846A (ko) 2003-06-25
SK288065B6 (sk) 2013-04-03
KR100819679B1 (ko) 2008-04-04
MY134559A (en) 2007-12-31
EA200300580A1 (ru) 2003-10-30
PE20020802A1 (es) 2002-09-10
HUP0301842A2 (hu) 2003-09-29
DK1341531T3 (da) 2007-05-14
AU4319202A (en) 2002-06-24
NO324324B1 (no) 2007-09-24
UA74849C2 (en) 2006-02-15
HUP0301842A3 (en) 2010-03-29
AR035927A1 (es) 2004-07-28
CN1486184A (zh) 2004-03-31
DZ3453A1 (fr) 2002-06-20
HU228117B1 (en) 2012-11-28
NZ525854A (en) 2004-06-25
EP1341531A2 (en) 2003-09-10
WO2002047671A2 (en) 2002-06-20
PT1341531E (pt) 2007-04-30
HRP20030383A2 (en) 2005-10-31
IL155960A0 (en) 2003-12-23
CZ20031351A3 (cs) 2003-11-12
HK1059731A1 (en) 2004-07-16
HRP20030383B1 (hr) 2007-12-31
DE60126132T2 (de) 2007-10-18
EP1341531B1 (en) 2007-01-17
CY1106366T1 (el) 2011-10-12
IL155960A (en) 2009-06-15
PL362688A1 (en) 2004-11-02
DE60126132D1 (de) 2007-03-08
SK5592003A3 (en) 2003-12-02
CA2427227A1 (en) 2002-06-20
SI1341531T1 (sl) 2007-06-30
TWI305204B (en) 2009-01-11
AU2002243192B2 (en) 2006-07-20
WO2002047671A3 (en) 2003-03-06
MXPA03004292A (es) 2004-02-12
ES2278804T3 (es) 2007-08-16
NO20032236D0 (no) 2003-05-16
PL212199B1 (pl) 2012-08-31
BR0115427A (pt) 2003-10-07
EA005954B1 (ru) 2005-08-25
NO20032236L (no) 2003-07-10
US20050261495A1 (en) 2005-11-24
JP2004517090A (ja) 2004-06-10

Similar Documents

Publication Publication Date Title
ECSP034600A (es) Compuestos de lactama
HN1999000154A (es) 1,2,3,4 tetrahidroquinolinas 2 sustituidas 4 - carboxiamino sustituidas.
NO20053246D0 (no) Kondensert 1,3-dihydroimidazol-ringforbindelse.
ATE404528T1 (de) 7,9 substituierte tetracyclinverbindungen
MY126559A (en) Fungicidal 2-methoxybenzophenones
ATE289640T1 (de) Amidofunktionelle aminopolydiorganosiloxane
DE60225341D1 (de) Neue 1,2,4-triazolverbindung
DE69803907D1 (de) Fungizide 2-Methoxybenzophenone
DK1385515T3 (da) Spiropyrazole forbindelser
MXPA04003886A (es) Tiofen- y tiazolsulfonamidas como agentes antineoplasticos.
PT1389213E (pt) Formulacoes de 3,7-diazabiciclo 3,3,1¿ como compostos antiarritmicos
MY141607A (en) Lactam compound
BR0205067B1 (pt) máquina semeadora.
AR028248A1 (es) Nuevos compuestos 2,3,4,5-tetrahidro-1h-(1,4) diazepino (1,7-a) indol
SV2003000981A (es) Fenil-heterociclil-eteres ref. pcs10973
TR199901017A2 (xx) B�cek ilac� terkibi.
EA200100854A1 (ru) Кальций-литические соединения
GB9918429D0 (en) Organic compounds
MXPA03009315A (es) 1.3-dionas carbociclicas tiazolil-substituidas como agentes pesticidas.
DK1073447T3 (da) N1-modificerede glycopeptider
BR0205298B1 (pt) máquina de semeadura.
DE60213084D1 (de) 3,7-DIAZABICYCLOc3.3.1Ü-FORMULIERUNGEN ALS ANTIARRHYTHMIKA
ITTO20020747A1 (it) Composizione.
DK1497256T3 (da) Substituerede 1,5-diaminopentan-3-ol-forbindelser
ITTO20020745A1 (it) Composizione.